Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

PROPOSED ADOPTION OF THE 2026 SHARE INCENTIVE SCHEME

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**" or "**Sihuan Pharmaceutical**", together with its subsidiaries, collectively the "**Group**") is pleased to announce that on 8 May 2026, the Board resolved to propose the adoption of the 2026 Share Incentive Scheme (the "**2026 Share Incentive Scheme**"). The 2026 Share Incentive Scheme will constitute a share scheme under Chapter 17 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and its provisions will comply with the requirements thereunder.

The 2026 Share Incentive Scheme aims to further improve the Group's long-term incentive and restraint mechanism, attract, retain and motivate outstanding management talent, professional research and development technical talent and core business talent in the Group's medical aesthetics segment, fully unleash the initiative, creativity and sense of responsibility of the core team, and closely align the personal value of employees with the long-term development of the Group and the overall interests of the shareholders, so as to jointly drive the sustained and healthy development of the Group in core areas such as medical aesthetics product research and development, compliant operations, brand building and market expansion, with a view to becoming a globally leading and nationally renowned leader in the medical aesthetics and healthcare industry.

The 2026 Share Incentive Scheme shall take effect subject to (i) the shareholders passing a resolution at the general meeting to approve the adoption of the 2026 Share Incentive Scheme; and (ii) the Stock Exchange granting approval for the listing of, and permission to deal in, the shares to be allotted and issued in respect of any awards that may be granted pursuant to the terms and conditions of the 2026 Share Incentive Scheme.

As at the date of this announcement, save for the share option scheme adopted at the general meeting of the Company held on 24 October 2017 (the "**Share Option Scheme**") and the 2022 Share Award Scheme adopted by the Board on 25 October 2022 (which does not involve any issue of new shares by the Company, transfer of treasury shares or grant of options over any new securities), the Company has no other effective and subsisting share schemes. In order to further optimise the Group's equity incentive arrangements and having considered the updates to the Listing Rules (including, but not limited to, the requirements relating to treasury shares), the Board has resolved to adopt the 2026 Share Incentive Scheme to replace the Share Option Scheme. Upon the approval of the 2026 Share Incentive Scheme at the general meeting and it becomes effective, no further options will be granted under the Share Option Scheme. However, any options already granted but not yet exercised under the Share Option Scheme before such adoption shall remain valid and exercisable in accordance with their respective terms, and the existing rights enjoyed by the relevant grantees under that scheme shall not be affected.

General

The Company will convene a general meeting for the shareholders to consider and, if thought fit, pass resolutions to approve, among other things, the adoption of the 2026 Share Incentive Scheme. A circular of the Company containing, among other things, (i) the proposed adoption of the 2026 Share Incentive Scheme; (ii) the principal terms of the 2026 Share Incentive Scheme; and (iii) the notice convening the general meeting, is expected to be published and/or despatched to the shareholders in due course in accordance with the requirements of the Listing Rules.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 8 May 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.